FDA approves Cymbalta for fibromyalgia

Cymbalta (duloxetine HCl, from Eli Lilly) has been approved for the management of fibromyalgia in adults. In two clinical trials, 51% and 55% of patients taking Cymbalta had a 30% improvement on the Brief Pain Inventory (BPI) 24-hour average pain scale. Also, 65% and 66% of patients taking Cymbalta reported feeling better at endpoint as measured by the Patient Global Impression of Improvement (PGI-I) scale.

Cymbalta is already indicated for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain in adults ≥18 years of age.

For more information call (800) LILLY-RX or visit www.cymbalta.com.